Key Drivers
- High liquidity
- Large operating losses
- Negative free cashflow
AIAI Summary
EyePoint has evolved from a cash‑burn biotech into a late‑stage, binary commercialization bet—its mid‑2026 pivotal DURAVYU readouts plus management's ~Q4‑2027 runway will likely determine whether the company re‑rates to justify current analyst targets or requires dilutive financing, so investors should prioritize trial outcomes, quarterly burn vs. runway, and commercialization execution (manufacturing/payer readiness) as primary triggers.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High liquidity
- •Large operating losses
- •Negative free cashflow
Strong balance sheet and ample liquid investments (cash $101.97M, investments $204.27M, current ratio 8.88, debt/equity 0.19) sharply contrast with unsustainable operating losses (FY net loss $231.96M, EPS -$3.17, negative EBITDA) and deeply negative free cash flow (-$243.24M) driven by R&D-heavy expenses far exceeding revenue.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Support base forming
- •Quick oversold drop
Over the last month the stock slid ~13.8% from $15.33 to $13.22, carving a $13.00–$13.50 support band amid lower highs (peak $18.34) that keep the bias bearish unless $15–$16 and ultimately $18.34 are reclaimed.
Rapid fall from $18.34 to $13.22 in early
Sentiment & News
Key News Insights:
- •Phase 3 progress
- •>$300M cash
- •Buy consensus
EyePoint reported dosing starts and on‑track pivotal Phase 3 trials for DURAVYU, >$300M cash runway into Q4‑2027, fresh commercial hires and analyst Buy consensus alongside new institutional buying.
Progress on clinical milestones, strong liquidity and growing commercial/institutional support meaningfully de‑risk near‑term execution and could bolster the stock ahead of mid‑2026 data
Similar Companies in Healthcare
Other companies in the same sector with AI ratings